Johnson & Johnson Earnings: Bullish on Innovative Medicine
Update: 2025-12-22
Description
Johnson & Johnson, the healthcare giant, is set to release its Q4 2025 earnings on Jan 21, with analysts expecting a 24% jump in EPS to $2.53. The company has beaten estimates for four straight quarters, driven by strong drugs, devices, and consumer products in areas like cancer treatment and orthopedics. Revenue climbed 6.8% in Q3 to $23.99B, beating forecasts, and adjusted EPS rose 15.7% to $2.80. The stock has surged 43.7% over the past 52 weeks and 42.7% YTD, outperforming the S&P 500 and healthcare sector ETF. Recent phase three data from the MajesTEC-three trial showed their drug TECVAYLI combined with DARZALEX FASPRO cut the risk of disease progression or death by 83% in multiple myeloma patients, sending shares up 3.3% on Dec 10. Analysts remain bullish with a moderate buy rating, an average price target of $211.12, and some seeing as high as $240.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
